 NEW YORK and LONDON, Feb. 01, 2021 GLOBE NEWSWIRE -- Akari Therapeutics, Plc Nasdaq: AKTX, a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement C5 andor leukotriene LTB4 systems are implicated, today announced that it is developing a second clinical candidate, votucalis, which specifically inhibits histamine. 